title: Letter by Johnson et al regarding article, "Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry".
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Johnson
authors.forename: Julian W
authors.initials: JW
authors.lastname: Strange
authors.forename: Andreas
authors.initials: A
authors.lastname: Baumbach
mesh_terms: D000991:Antithrombins / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy*; D010446:Peptide Fragments / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention
chemical_list: D000991:Antithrombins; D005343:Fibrinolytic Agents; D010446:Peptide Fragments